Mirum Pharmaceuticals, Inc.(MIRM)Earnings, Financials & Key RatiosMirum Pharmaceuticals, Inc. (MIRM) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company shows promising revenue growth of 49.8% in 2025Q4, the $19.0M in quarterly stock-based compensation and the $1.5B accumulated deficit warrant further investigation into the quality of long-term earnings.
Mirum Pharmaceuticals, Inc. (MIRM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Mirum Pharmaceuticals, Inc. (MIRM) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $13.43vs $0.40-3257.5% | $160Mvs $148M+7.9% |
| Q1 2026 | Feb 25, 2026 | $0.11vs $0.02-650.0% | $149Mvs $143M+4.5% |
| Q4 2025 | Nov 4, 2025 | $0.05vs $0.10+150.0% | $133Mvs $141M-5.6% |
| Q3 2025 | Aug 6, 2025 | $0.12vs $0.31+61.3% | $128Mvs $130M-1.8% |
Recent stock market news and headlines for Mirum Pharmaceuticals, Inc. (MIRM)
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Key metrics vs top competitors for Mirum Pharmaceuticals, Inc. (MIRM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $121.91 | $6.12B | -259.38 | 54.74% | -4.48% | -8.65% | — | |
| $313.04 | $41.77B | 134.35 | 65.19% | 13.46% | 98.29% | — | |
| $33.70 | $3.31B | -5.78 | 20.13% | -91.03% | — | — | |
| $25.77 | $4.41B | 11.25 | 11.87% | 34.3% | 35.65% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $85.44 | $7.09B | 10.98 | 114.51% | -22.58% | — | — |
Mirum Pharmaceuticals, Inc. (MIRM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Mirum Pharmaceuticals, Inc. (MIRM) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 6, 2026·SEC
May 4, 2026·SEC
Apr 27, 2026·SEC
Get notified when MIRM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Mirum Pharmaceuticals, Inc. (MIRM) stock FAQ — growth, dividends, profitability & financials explained
Mirum Pharmaceuticals, Inc. (MIRM) reported $409.7M in revenue for fiscal year 2025.
Mirum Pharmaceuticals, Inc. (MIRM) grew revenue by 54.7% over the past year. This is strong growth.
Mirum Pharmaceuticals, Inc. (MIRM) reported a net loss of $798.8M for fiscal year 2025.
Mirum Pharmaceuticals, Inc. (MIRM) has a return on equity (ROE) of -8.6%. Negative ROE indicates the company is unprofitable.
Mirum Pharmaceuticals, Inc. (MIRM) had negative free cash flow of $172.6M in fiscal year 2025, likely due to heavy capital investments.
